Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2012-11-13 Regulatory Filings
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo announces submission of a New Drug Application for KW-2246 (Abstral®) in Japan
Regulatory Filings Classification · 1% confidence The document is explicitly titled as a "Press release" dated November 13, 2012, announcing that Orexo's partner has submitted a New Drug Application ("NDA") in Japan for a product. This is a specific corporate announcement regarding regulatory progress (drug application submission) but is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a formal legal filing. Since it details a specific corporate action/update that doesn't fit the primary financial report categories, and it is a formal announcement, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-financial regulatory news, or potentially 'LTR' if viewed as a regulatory event, but RNS is the broader fit for general regulatory announcements not covered elsewhere. Given the options, RNS (Regulatory Filings) is the most appropriate general category for a press release detailing a regulatory submission update.
2012-11-13 English
Orexo meddelar att en registreringsansökan för KW-2246 (Abstral®) lämnats in i Japan
Regulatory Filings Classification · 1% confidence The document is a press release dated November 13, 2012, announcing that Orexo's partner, Kyowa Hakko Kirin, has submitted a New Drug Application (NDA) in Japan for the product KW-2246 (Abstral®). This is an announcement regarding a regulatory submission/filing for a pharmaceutical product, not the final regulatory filing itself (like a 10-K or AR). Since it is a specific announcement about a regulatory action (drug application submission) that doesn't fit neatly into the other specific categories (like M&A, Capital Change, or Director Dealing), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially 'LTR' if interpreted as a legal/regulatory update, but RNS is the broader fallback for non-standard regulatory news. Given the context of a press release announcing a specific regulatory step (NDA submission), RNS is the most appropriate general classification for this type of corporate news release that isn't a core financial report or specific corporate action like a dividend or share buyback.
2012-11-13 Swedish
Antal aktier och röster i Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release (1431 characters) dated October 31, 2012, titled "Antal aktier och röster i Orexo" (Number of shares and votes in Orexo). It explicitly states that the total number of shares and votes has changed due to the exercise of stock options, and it reports the final count as of the last trading day of the month. This directly relates to changes in the company's capital structure or share count. This fits best under 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general regulatory filing (RNS) because it is highly specific to share count changes, nor is it a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), as it reports the total outstanding shares, not an insider's transaction or a threshold crossing by a major shareholder.
2012-10-31 Swedish
Number of shares and votes in Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release dated October 31, 2012, announcing a change in the total number of shares and votes due to the exercise of warrants. This directly relates to a change in the company's capital structure (share count). Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing changes in the total number of outstanding shares. It is not an earnings release (ER), a dividend notice (DIV), or a director's dealing (DIRS). Given its specific nature regarding share count changes, SHA is preferred over the general 'RNS' fallback.
2012-10-31 English
Orexo announces dosing of first patient with OX51 in phase II clinical trial on prevention of procedure-induced pain
Regulatory Filings Classification · 1% confidence The document is explicitly titled and formatted as a "Press release" dated October 30, 2012. It announces a specific corporate event: the dosing of the first patient in a Phase II clinical trial for their product OX51. This type of announcement, detailing operational progress (clinical trial start) rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or news releases. Since it is a press release announcing operational progress and is not a specific financial report, dividend notice, or management change, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that don't fit the highly specific financial codes. The document length (4243 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2012-10-30 English
Orexo meddelar dosering av första patienten med OX51 i en klinisk fas II studie för förebyggande av procedurinducerad smärta
Legal Proceedings Report Classification · 1% confidence The document is a press release dated October 30, 2012, announcing that Orexo has dosed the first patient in a Phase II clinical study for their product OX51. It details the product, the market need, and the next steps in development. This type of announcement, which is a specific operational/clinical update rather than a mandatory financial filing (like 10-K, ER, or IR), fits best under the general category for regulatory announcements or news releases that don't fit other specific financial/governance codes. Since it is a specific announcement about clinical progress and not a general regulatory filing fallback, and it is not a standard financial report, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for corporate news releases not covered elsewhere, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are clearly incorrect. Given the options, RNS serves as the best fit for a general corporate news announcement of this nature.
2012-10-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.